Documentary About Sudan Wins Award at GFF

Photo showing all the participants in the Final Cut Venice 2023
workshop
Photo showing all the participants in the Final Cut Venice 2023 workshop
TT

Documentary About Sudan Wins Award at GFF

Photo showing all the participants in the Final Cut Venice 2023
workshop
Photo showing all the participants in the Final Cut Venice 2023 workshop

The documentary “Sudan, When Poems Fall Apart” has won the GFF Award at the Final Cut Venice 2023, an initiative aimed at supporting films in post-production phase. This year’s edition of the initiative saw the participation of seven works from the Middle East and North Africa.

El Gouna Film Festival (GFF) described the winning documentary as an “extraordinary” project. “The documentary draws a deep picture of Sudan by seamlessly narrating the stories of four women: Shajan, Marmal, Maha, and Rafida. The documentary is a sincere love poem about Sudan. It uses the overlapping stories of the four women to recreate the image of an ongoing revolution,” GFF said in a statement on Tuesday.

The documentary is a French-Tunisian co-production, directed by Hind Meddeb who has an impressive work record including films like “Paris, Stalingrad”, and “Tunisian Clash”, which shed lights on the reality of rappers in Tunisia after the fall of Ben Ali’s regime. In appreciation of the project, GFF offers a money prize of $5,000 to support the post-production stages.

“We are delighted to screen and support the extraordinary project ‘Sudan, When Poems Fall Apart’ at the Final Cut Venice 2023. This award emphasizes the festival’s commitment to the creative voices in the Arabic cinema, and to building sustainable connections in the Arabic cinema industry,” said Intishal al-Timimi, GFF director. He also congratulated the talented teams behind the film project “She Was not Alone”, scheduled to participate in the festival next month.

Young Sudanese actor, Mustafa Shehata, said El Gouna Film Festival shed lights on the Sudanese cinema and celebrates it. “This interest manifested in the participation of the film ‘You Die at Twenty’ in the 2019 edition, during which it won the Golden Award for Best Feature Film. That edition also screened the film ‘Talk About Trees’ by director Suhaib Qasim al-Bari, which also won the Best Documentary Film Award,” he told Asharq Al-Awsat.

Shehata, the lead actor in ‘You Will Die at Twenty’, said “the interest in Sudanese cinema in the upcoming edition of GFF means a lot to us in light of the war circumstances in our country,” especially since the Sudanese cinema had started to recover in the few past years. He also said ‘You Will Die at Twenty’ by director Amjad Abu al-Ala was a great comeback opportunity for the Sudanese cinema, along with ‘Tree Talk’ and ‘Offside Khartoum’ by Marwa Zein. This celebration from GFF reflects “the solidarity with the Sudanese cinema, which insists on surviving despite everything.”

The festival announced that the film project “She Was Not Alone” also won the GFF Award. It’s an Iraqi-Saudi-US co-production, directed by Hussein Al-Assadi, and produced by Ishtar Iraq Film Production. The film is a poetic contemplation of the life of a Bedouin woman named Fatima, who lives alone in the wetlands of Iraq with her beloved animals. The film explores the difficult choices that the character faces. It was selected to participate in the GFF post-production category, and compete for awards and grants provided by the festival and a number of influential partners in the film industry.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”